A Multicentre, Retrospective Chart Review Study to Describe the Clinical Profile of Idiopathic Pulmonary Fibrosis (IPF) Patients Treated With Nintedanib (OFEV) in Real-world Practice in Spain.
Phase of Trial: Phase IV
Latest Information Update: 02 Aug 2019
Price : $35 *
At a glance
- Drugs Nintedanib (Primary) ; Antineoplastics; Protein kinase inhibitors
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 07 Jun 2018 Status changed from active, no longer recruiting to completed.
- 25 Apr 2018 Planned End Date changed from 30 Apr 2018 to 31 May 2018.
- 25 Apr 2018 Planned primary completion date changed from 30 Apr 2018 to 31 May 2018.